Rockin Robin SongFlying The Web For News.
RobinPost Logo Amazon Prime Deals





Globe NewsWire News Distribution Service


Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2 open-label extension studies show PALSONIFY maintained lower IGF-1 levels and stable symptoms Treatment also resulted in stable or reduced pituitary tumor volumes for up to 48 weeks


Posted: 2026-06-14 18:45:00

Get Full News Story On GlobeNewsWire Press Release Service




More News From This Category
Press Release: Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Sun, 14 Jun 2026 22:07:39 +0000

VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the dose-escalation portion of its ongoing Phase 1 study evaluating ZW191, a folate receptor alpha (FRα)-targeting antibody-drug…

Read More ...


Press Release: Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Sun, 14 Jun 2026 16:07:41 +0000

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) and certain of its officers.

Read More ...


Press Release: Bitcoin Meets AI Trading: AIXAlpha Launches Free AI Strategy Contracts with Daily Settlement
Sun, 14 Jun 2026 13:07:42 +0000

LOS ANGELES, June 14, 2026 (GLOBE NEWSWIRE) -- As the Bitcoin ecosystem gains global momentum, AIXAlpha is proud to introduce a major leap in accessible AI-driven participation: the launch of BTC-focused AI Strategy Contracts.

Read More ...


Press Release: Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
Sun, 14 Jun 2026 10:07:45 +0000

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent…

Read More ...


Related Bing News Results
Best 15 press release distribution services 2026 (pros, cons, pricing)
Mon, 08 Jun 2026 10:28:08 GMT
Best 15 press release distribution services in 2026 ranked by use case. RedPress, PR Newswire, Business Wire, EIN Presswire pricing, pros, cons compared.

The 10 best press release distribution services for 2026
Sat, 06 Jun 2026 04:52:00 GMT
From AI-indexed wire distribution to boutique editorial review, these are the press release services that deliver real publisher placements without legacy wire pricing.














Blow Us A Whistle


Related Product Search/Búsqueda de productos relacionados

Amazon Logo

Visit Our New Print-On-Demand Stores On Printify and Zazzle
Printify Zazzle